daraxonrasib + docetaxel
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
NSCLC (Non-small Cell Lung Cancer)
Conditions
NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer)
Trial Timeline
May 6, 2025 → Dec 1, 2030
NCT ID
NCT06881784About daraxonrasib + docetaxel
daraxonrasib + docetaxel is a phase 3 stage product being developed by REVOLUTION Medicines for NSCLC (Non-small Cell Lung Cancer). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06881784. Target conditions include NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC.
What happened to similar drugs?
7 of 20 similar drugs in NSCLC (Non-small Cell Lung Cancer) were approved
Approved (7) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06881784 | Phase 3 | Recruiting |
Competing Products
20 competing products in NSCLC (Non-small Cell Lung Cancer)